Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

ClinicalTrials.gov ID: NCT05315700

Public ClinicalTrials.gov record NCT05315700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 6:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Study identification

NCT ID: NCT05315700
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: ORIC Pharmaceuticals; Industry
Enrollment: 350 participants

Conditions and interventions

Conditions

Solid Tumors

Interventions

Chemotherapy drug Drug
ORIC-114 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 9, 2022
Primary completion: Aug 31, 2026
Completion: Aug 31, 2027
Last update posted: Aug 4, 2025

2022 – 2027

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 17

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
City of Hope	Huntington Beach	California	90813	Recruiting
City of Hope	Irvine	California	92618	Recruiting
City of Hope	Long Beach	California	90813	Recruiting
University of California, San Francisco	San Francisco	California	94122	Recruiting
Yale Cancer Center	New Haven	Connecticut	06510	Recruiting
Georgetown University	Washington D.C.	District of Columbia	20007	Recruiting
Mayo Clinic	Jacksonville	Florida	32224	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Northwestern University	Chicago	Illinois	60611	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Mayo Clinic	Rochester	Minnesota	55905	Recruiting
NYU Langone Health Perlmutter Cancer Center	New York	New York	10016	Recruiting
Duke Cancer Institute	Durham	North Carolina	27710	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
Spartanburg Regional Healthcare System	Spartanburg	South Carolina	29303	Recruiting
Next Oncology	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05315700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 4, 2025 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05315700 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →